Spinal osteosarcoma in the paediatric age group: Case series and literature review

Egea-Gámez, Rosa M.; Ponz-Lueza, V.; Cendrero-Torrado, A.; Martínez-González, C.; Certucha-Barragán, J.A.; González-Díaz, Rafael

doi:10.1016/j.recote.2018.09.001

Cited by 4 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although OS can initiate in nearly any bone within the human skeleton, the metaphyseal growth plate in long bones is the most common site. Forty-two percent of OS occurs in the distal femur, 19% in the proximal tibia, and 10% in the proximal humerus. − During the development of OS, a ball-like mass develops in a radial pattern that eventually penetrates the cortical bone, and as growth continues, it compresses surrounding muscles. − During surgical resection, the primary goal is to achieve the complete removal of the tumor with wide excisions. There are two main surgeries to accomplish this: limb salvage surgery and amputation. , Limb salvage surgery often involves the use of prosthetics, but prosthetic materials cause incomplete and extended time to heal, prolonged non-weight-bearing periods, and increased risk of fractures, infections, degenerative arthritis, and joint instability. − ,,,− Therefore, the inadequacy of current therapies urges the development of novel treatment options for regeneration of bone loss to repair bone voids.…”

Section: Discussionmentioning

confidence: 99%

Systemic Cisplatin Does Not Affect the Bone Regeneration Process in a Critical Size Defect Murine Model

Brozovich,

Lenna,

Brenner

et al. 2024

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Osteosarcoma (OS) is the most common primary malignant bone tumor, and the current standard of care for OS includes neoadjuvant chemotherapy, followed by an R0 surgical resection of the primary tumor, and then postsurgical adjuvant chemotherapy. Bone reconstruction following OS resection is particularly challenging due to the size of the bone voids and because patients are treated with adjuvant and neoadjuvant systemic chemotherapy, which theoretically could impact bone formation. We hypothesized that an osteogenic material could be used in order to induce bone regeneration when adjuvant or neoadjuvant chemotherapy is given. We utilized a biomimetic, biodegradable magnesium-doped hydroxyapatite/type I collagen composite material (MHA/Coll) to promote bone regeneration in the presence of systemic chemotherapy in a murine critical size defect model. We found that in the presence of neoadjuvant or adjuvant chemotherapy, MHA/Coll is able to enhance and increase bone formation in a murine critical size defect model (11.16 ± 2.55 or 13.80 ± 3.18 versus 8.70 ± 0.81 mm 3 ) for pre-op cisplatin + MHA/Coll (p-value = 0.1639) and MHA/Coll + post-op cisplatin (p-value = 0.1538), respectively, at 12 weeks. These findings indicate that neoadjuvant and adjuvant chemotherapy will not affect the ability of a biomimetic scaffold to regenerate bone to repair bone voids in OS patients. This preliminary data demonstrates that bone regeneration can occur in the presence of chemotherapy, suggesting that there may not be a necessity to modify the current standard of care concerning neoadjuvant and adjuvant chemotherapy for the treatment of metastatic sites or micrometastases.

show abstract

Section: Discussionmentioning

confidence: 99%

Systemic Cisplatin Does Not Affect the Bone Regeneration Process in a Critical Size Defect Murine Model

Brozovich,

Lenna,

Brenner

et al. 2024

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

show abstract

“… 8 Because of the difficulty in differentiating between its clinical, radiological and histopathological features, osteosarcoma of the spine is frequently initially misinterpreted as an aggressive benign vertebral lesion like osteoblastoma or aneurysmal bone cyst and can sometimes can be mistaken for chondrosarcoma or malignant giant cell tumour (GCT). 1 , 9 A biopsy is therefore usually indicated. The atypical GCRO variant is characterised by an abundance of osteoclast-like giant cells and paucity of osteoid tumour, 3 resulting in confusion with GCTs.…”

Section: Introductionmentioning

confidence: 99%

Giant cell-rich osteosarcoma of the lumbar spine – A rare entity

Kalekar,

Sharma,

Paidlewar

et al. 2024

South African Journal of Radiology

View full text Add to dashboard Cite

Giant cell-rich osteosarcoma (GCRO) is a rare variant of osteosarcoma. A significant diagnostic hurdle is presented by the lesion’s uncommon appearance on histopathology. This report presents a case of a 59-year-old female patient diagnosed with GCRO.Contribution: While it is extremely difficult to distinguish GCRO from malignant giant cell tumour, it is important to do so because of the difference in prognosis and management. Distinctive anatomy of the lumbar spine increases the risks associated with surgical excision.

show abstract

“…Worldwide, osteosarcoma contributes to a remarkable share of cancer-related death [ 3 ]. At the pathological level, the high rate of metastasis occurrence takes the major charge for the unfavorable prognosis of osteosarcoma [ 4 , 5 ]. Although adjuvant chemotherapy and novel surgeries are widely utilized to cure osteosarcoma, the results remain unsatisfied [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Novel circular RNA circATRNL1 accelerates the osteosarcoma aerobic glycolysis through targeting miR-409-3p/LDHA

et al. 2021

View full text Add to dashboard Cite

In recent researches, circular RNAs (circRNAs) have been shown to exert critical functions in osteosarcoma biology. Nevertheless, the contribution of circRNAs to osteosarcoma remains largely unclear. Results indicated that expression of circATRNL1 was higher in osteosarcoma tissues and cells. The high-expression of circATRNL1 was significantly correlated with aggressive features and acted as an independent risk factor for osteosarcoma patients' overall survival. Functionally, our findings demonstrate that circATRNL1 promotes the osteosarcoma aerobic glycolysis in vitro. Mechanistically, circATRNL1 up-regulated the expression level of LDHA, which was also targeted by miR-409-3p. Therefore, circATRNL1 exerted the accelerative roles of osteosarcoma aerobic glycolysis through miR-409-3p/LDHA axis.In conclusion, circATRNL1 promoted osteosarcoma progression by enhancing glycolysis via circATRNL1/miR-409-3p/LDHA axis, which may inspire a novel therapeutic target for osteosarcoma.

show abstract

Spinal osteosarcoma in the paediatric age group: Case series and literature review

Cited by 4 publications

References 22 publications

Systemic Cisplatin Does Not Affect the Bone Regeneration Process in a Critical Size Defect Murine Model

Systemic Cisplatin Does Not Affect the Bone Regeneration Process in a Critical Size Defect Murine Model

Giant cell-rich osteosarcoma of the lumbar spine – A rare entity

Novel circular RNA circATRNL1 accelerates the osteosarcoma aerobic glycolysis through targeting miR-409-3p/LDHA

Contact Info

Product

Resources

About